TriNav Advance is the fourth FDA-cleared PEDD device in TriSalus’s portfolio, joining the TriNav Infusion System and TriNav ...

Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small ...

Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...

Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 ...

The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.

Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full ...

This episode makes the case for moving HER2-targeted therapy into the first-line setting. The panel describes how a frontline ...

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

The FDA has approved lirafugratinib (Lyrfigtu), an investigational oral FGFR2 inhibitor, as a treatment for patients with ...

Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma. The FDA has approved belzutifan (Welireg) in ...

The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies. The executive summary released by the FDA ...

A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of ...